本帖最后由 老马 于 2012-1-13 21:20 编辑 * x2 Z9 F* P3 X( W7 x( E: {
: z d# _0 J0 O) n1 j- R, X. q
爱必妥和阿瓦斯丁的比较
: f& A( ~& `; M3 y# A2 J; y$ R
- I' ^$ o L4 X5 Y% [7 m) khttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
# @! b$ J& d$ F, d' z" m
: t3 s; M5 D( t, n
$ ~& z% h* [2 T
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/* a% J2 e% P* P( Q u- F7 I& Z+ S
==================================================
7 I! E9 h$ } l) T( y) y$ H8 ZOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
; `2 _* g: L1 d! k. f( R/ E. qPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
9 |1 G5 E# N; b! H. pResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.- J1 I* F: k* l6 l2 D! `
|